USS Investment Management Ltd Purchases 22,335 Shares of Pfizer Inc. $PFE

USS Investment Management Ltd grew its position in shares of Pfizer Inc. (NYSE:PFE) by 2.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 970,841 shares of the biopharmaceutical company’s stock after buying an additional 22,335 shares during the quarter. USS Investment Management Ltd’s holdings in Pfizer were worth $27,256,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vermillion Wealth Management Inc. lifted its position in Pfizer by 19.4% in the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 382 shares in the last quarter. Triad Wealth Partners LLC increased its holdings in shares of Pfizer by 1.9% in the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after purchasing an additional 386 shares in the last quarter. Eagle Capital Management LLC increased its holdings in shares of Pfizer by 0.3% in the 1st quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after purchasing an additional 390 shares in the last quarter. ETF Store Inc. raised its stake in shares of Pfizer by 3.8% in the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after purchasing an additional 396 shares during the last quarter. Finally, Mattern Wealth Management LLC lifted its holdings in shares of Pfizer by 4.6% during the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after purchasing an additional 400 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE PFE opened at $24.08 on Wednesday. Pfizer Inc. has a 52 week low of $23.11 and a 52 week high of $28.75. The firm has a market capitalization of $137.23 billion, a P/E ratio of 18.38 and a beta of 0.34. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The company has a 50-day moving average price of $25.81 and a 200-day moving average price of $26.27.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 7.1%. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on PFE. BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a research report on Tuesday, June 23rd. CICC Research initiated coverage on shares of Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 target price on the stock. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Sunday, June 21st. UBS Group restated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, May 27th. Finally, Morgan Stanley lifted their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $28.82.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s GLP-1 drug Ecnoglutide cleared a preliminary review for possible inclusion in China’s basic medical insurance drug catalogue, a potentially meaningful commercialization step for its obesity/diabetes pipeline. Article Title
• Positive Sentiment: Investor commentary continues to frame Pfizer as a value and income stock, citing its high dividend yield and low valuation metrics, which may be attracting bargain hunters. Article Title
• Positive Sentiment: Pfizer also signed a SuperHuman platform license agreement with Distributed Bio, suggesting continued dealmaking to strengthen its drug-development pipeline. Article Title
• Neutral Sentiment: Multiple market recaps said Pfizer traded lower while the market improved, but the stock still outperformed some competitors, indicating the move may have been more about sector sentiment than company-specific news. Article Title
• Neutral Sentiment: Pfizer completed a real-world COVID-19 vaccine study and investors are awaiting data release, which could matter for sentiment but is not yet a confirmed catalyst. Article Title
• Negative Sentiment: Bearish commentary continues to focus on fading COVID franchise sales, with one article noting sharp declines in Comirnaty and Paxlovid revenue, reinforcing concerns about Pfizer’s near-term growth outlook. Article Title

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.